0000950170-24-044836.txt : 20240416
0000950170-24-044836.hdr.sgml : 20240416
20240416165412
ACCESSION NUMBER: 0000950170-24-044836
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240416
DATE AS OF CHANGE: 20240416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weber Darin J.
CENTRAL INDEX KEY: 0001936228
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40560
FILM NUMBER: 24848492
MAIL ADDRESS:
STREET 1: C/O PROKIDNEY CORP.
STREET 2: 3929 WESTPOINT BLVD., SUITE G
CITY: WINSTON-SALEM
STATE: NC
ZIP: 27103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROKIDNEY CORP.
CENTRAL INDEX KEY: 0001850270
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981586514
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 FRONTIS PLAZA BLVD.
STREET 2: SUITE 250
CITY: WINSTON-SALEM
STATE: NC
ZIP: 27103
BUSINESS PHONE: 336-999-7028
MAIL ADDRESS:
STREET 1: 2000 FRONTIS PLAZA BLVD.
STREET 2: SUITE 250
CITY: WINSTON-SALEM
STATE: NC
ZIP: 27103
FORMER COMPANY:
FORMER CONFORMED NAME: Social Capital Suvretta Holdings Corp. III
DATE OF NAME CHANGE: 20210310
4
1
ownership.xml
4
X0508
4
2024-04-01
0001850270
PROKIDNEY CORP.
PROK
0001936228
Weber Darin J.
C/O PROKIDNEY CORP
2000 FRONTIS PLAZA BLVD, SUITE 250
WINSTON-SALEM
NC
27103
false
true
false
false
SVP of Regulatory Development
true
Class A Ordinary Shares
2024-04-01
4
S
false
300
1.69
D
273773
D
Class A Ordinary Shares
2024-04-12
4
S
false
84103
1.73
D
189670
D
The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.77, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Todd Girolamo as Attorney-in-Fact
2024-04-16